Click image to view original image
Product name:Dutasteride (Avodart)
CAS No.: 164656-23-9
MF:C27H30F6N2O2
MW:528.53
Character:White powder
Assay:99%
Brand Name: Sex Enhancers
Place of Origin: China
Standard: Enterprise Standard
Certification: ISO9001
Delivery Time: Within 24h After The Payment Confirm
Supply Ability: 500kg/month
Packaging Details: as requirement
Payment Terms: Western unio, MoneyGram, T/T
Usage:
Used in the treatment of benign prostatic hyperplasia. Dual inhibitor of 5A-reductase isoenzymes type 1 and 2; Structurally related to Finasteride.
Product description:
Dutasteride (trademark name Avodart) is a dual 5-a Reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). Used for benign prostatic hyperplasia; However, it increases the risk of erectile dysfunction and decreased sexual desire.
Dutasteride useful for the symptoms of benign prostatic hyperplasia (BPH); Colloquially known as an "enlarged prostate". In those who are being regularly screened 5-alpha-reductase inhibitor (finasteride and dutasteride) reduce the overall risk of being diagnosed with prostate cancer however there is insufficient data to determine if they have an effect on the risk of death and may increase the chance of more serious cases. This class of medications increases rates of erectile dysfunction (with between 5% and 9% developing problems after starting their use). This is linked to lower quality of life and can cause stress in relationships. There is also an association with lowered sexual desire. It has been reported that these adverse sexual side effects may persist even after discontinuation of the drug. The FDA has added a warning to dutasteride about an increased risk of high-grade prostate cancer. While the potential for positive, negative or neutral changes to the potential risk of developing prostate cancer with dutasteride has not been established, evidence has suggested it may temporarily reduce the growth and prevalence of benign prostate tumors, but could also mask the early detection of prostate cancer. The primary area for concern is for patients who may develop prostate cancer whilst taking dutasteride for benign prostatic hyperplasia, which in turn could delay diagnosis and early treatment of the prostate cancer, thereby potentially increasing the risk of these patients developing high-grade prostate cancer.
Contact Details:
If you need this or you are interest in this kind of products, you are free to send me email or call me directly, we can talk more about the details of the products.No matter you become a customer to me or not at last, you are welcome to inquire from me!
Zhuzhou Yuancheng Hezhong Technology Development Co., Ltd.
Contact Person: Mr. Zhang Bo
Tel: +8618188938021
Fax: +86-731-22292057
Cell: +86-731-22292057
E-mail: YCWlb031@yccreate.com
